Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > (+)-Ibuprofen

(+)-Ibuprofen

pharmaceutical raw materials
(+)-Ibuprofen structure

(+)-Ibuprofen 

structure
  • CAS No:

    51146-56-6

  • Formula:

    C13H18O2

  • Chemical Name:

    (+)-Ibuprofen

  • Synonyms:

    Benzeneacetic acid,α-methyl-4-(2-methylpropyl)-,(αS)-;Benzeneacetic acid,α-methyl-4-(2-methylpropyl)-,(S)-;(αS)-α-Methyl-4-(2-methylpropyl)benzeneacetic acid;(+)-Ibuprofen;d-Ibuprofen;(S)-(+)-Ibuprofen;(S)-Ibuprofen;Dexibuprofen;(+)-(S)-Ibuprofen;(+)-Ibuprophen;(S)-2-(4-Isobutylphenyl)propionic acid;(S)-2-(4-Isobutylphenyl)propanoic acid;(+)-(S)-p-Isobutylhydratropic acid;(S)-2-(p-Isobutylphenyl)propionic acid;(+)-α-Methyl-4-(2-methylpropyl)benzeneacetic acid;(S)-(+)-4-Isobutyl-α-methylphenylacetic acid;(S)-(+)-2-(4-Isobutylphenyl)propionic acid;Seractil;(S)-(+)-p-Isobutylhydratropic acid;Nyfen;Ultraprofen;S-Optifen

  • Categories:

    Pharmaceutical Intermediates  >  Bulk Drug Intermediates

Description

(S)-(+)-Ibuprofen is the S-enantiomer of Ibuprofen. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.


Dexibuprofen is an ibuprofen. It has a role as a non-narcotic analgesic and a non-steroidal anti-inflammatory drug. It is an enantiomer of a levibuprofen.|Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability. For Metabolism, Enzymes, Carriers, Transporters Sections, refer to [Ibuprofen].

(+)-Ibuprofen Basic Attributes

206.28

206.28

671DKG7P5S

759814

DTXSID9048724

M - Musculo-skeletal system

2916399090

Characteristics

37.3

3.5

colourless, crystalline solid

1.0±0.1 g/cm3

54 °C

110 °C @ Press: 0.1 Torr

216.7±14.4 °C

1.519

insoluble

Store at RT

Safety Information

NONH for all modes of transport

3

R22;R63

S36/37-S45

Xn:Harmful;

Stable. Incompatible with strong oxidizing agents.

P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, P501

H302

|Warning|H302 (85.71%): Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 7 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Oral LD50 value in rats is 636 mg/kg. For more information, refer to [ibuprofen].

For more information, refer to [ibuprofen].

Drug Information

For more information, refer to [ibuprofen].

For more information, refer to [ibuprofen].

The time it take to reach peak plasma concentration is 2.25-5 hours post-administration of oral tablets containing 300mg of dexibuprofen. For more information, refer to [ibuprofen].|Mainly renal excretion. For more information, refer to [ibuprofen].|For more information, refer to [ibuprofen].

For more information, refer to [ibuprofen].|(S)-(+)-ibuprofen has known human metabolites that include 2-Hydroxyibuprofen and 3-Hydroxyibuprofen.

Oral tablets containing 300mg of dexibuprofen results in 2.2-4.7 hours. For more information, refer to [ibuprofen].

Like common NSAIDs, dexibuprofen is an active enantiomer of [ibuprofen] that suppresses the prostanoid synthesis in the inflammatory cells via inhibition of the COX-2 isoform of the arachidonic acid COX. For more information, refer to [ibuprofen].

dexibuprofen

(+)-Ibuprofen Use and Manufacturing

Uses

A nonsteroidal anti-inflammatory drug (NSAID); activity resides primarily in the (S)-isomer sedative Ibuprofen is a non-steroidal anti-inflammatory drug with diverse biochemical actions, most notably inhibiting COX-1 and COX-2 (IC50s = 2.6 and 1.53, μM, respectively). It is commonly synthesized as a racemic mixture of (S)- and (R)-isomers. (S)-Ibuprofen is an enantiomer that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form. (S)-Ibuprofen also inhibits activation of NF-κB more effectively than (R)-ibuprofen (IC50s = 62 and 122 μM, respectively). However, the enantiomers are equipotent in blocking superoxide formation, β-glucuronidase release, and LTB4 generation by stimulated neutrophils (IC50 values range from 0.14 to 0.58 μM). A majority of (R)-ibuprofen can be inverted to (S)-ibuprofen in humans after oral administration.

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:206.28
XLogP3:3.5
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:2
Rotatable Bond Count:4
Exact Mass:206.130679813
Monoisotopic Mass:206.130679813
Topological Polar Surface Area:37.3
Heavy Atom Count:15
Complexity:203
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

By inhibiting the synthesis of prostaglandins or other inflammatory mediators, it exhibits anti-inflammatory, analgesic and antipyretic effects. It is more potent than ibuprofen and takes effect more quickly.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • SMS Pharmaceuticals Ltd

    United States United States
    Active
  • SMS PHARMACEUTICALS LIMITED

    India India
    Active
  • SOLARA ACTIVE PHARMA SCIENCES LIMITED

    Brazil Brazil
    Active

Recommended Suppliers of (+)-Ibuprofen

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.